Last reviewed · How we verify
GIK and intensive insulin therapy
GIK (glucose-insulin-potassium) therapy combined with intensive insulin regimens improves myocardial metabolism and reduces ischemic injury by enhancing glucose uptake and oxidative metabolism in cardiac tissue.
GIK (glucose-insulin-potassium) therapy combined with intensive insulin regimens improves myocardial metabolism and reduces ischemic injury by enhancing glucose uptake and oxidative metabolism in cardiac tissue. Used for Acute myocardial infarction with intensive glycemic control.
At a glance
| Generic name | GIK and intensive insulin therapy |
|---|---|
| Also known as | GIKI2 |
| Sponsor | University of Monastir |
| Drug class | Metabolic therapy / Insulin-based combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
GIK therapy delivers a high-concentration glucose-insulin-potassium solution to shift myocardial metabolism toward glucose oxidation, which is more efficient under ischemic conditions than fatty acid oxidation. Intensive insulin therapy further optimizes glucose homeostasis and reduces inflammatory markers associated with acute coronary events. Together, these interventions aim to preserve cardiac function and reduce infarct size during acute myocardial infarction.
Approved indications
- Acute myocardial infarction with intensive glycemic control
Common side effects
- Hypoglycemia
- Hypokalemia
- Hyperglycemia rebound
- Phlebitis at infusion site
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GIK and intensive insulin therapy CI brief — competitive landscape report
- GIK and intensive insulin therapy updates RSS · CI watch RSS
- University of Monastir portfolio CI